OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
2256$10.2858

Abbisko Cayman Ltd

Biotechnology & Medical ResearchVerified

Capital Structure and Liquidity Abbisko maintains a strong liquidity position, with a current ratio of 4.98 and cash and equivalents of CNY 749.01 million, representing 31.8% of total assets. The company's debt-to-equity ratio is 0.16, indicating a conservative capital structure with minimal leverage. Custom valuations show a liquidity FPT of 1.2, suggesting robust short-term financial flexibility. ### Profitability and Returns The company's profitability is modest, with a net income of CNY 55.31 million and a return on equity (ROE) of 2.88%. These figures are below the industry median for ROE in the Biotechnology & Medical Research sector, which typically exceeds 10%. Gross profit equals total revenue, suggesting no cost of goods sold, which is unusual for a pharmaceutical company and may indicate a different business model or reporting structure. ### Segments and Geographic Exposure Abbisko's revenue is not segmented by geography or product in the provided data, but the company's operations are likely concentrated in China given the CNY financial reporting. There is no indication of significant international diversification. ### Growth Trajectory The company's revenue of CNY 612.12 million is stable, but there is no historical data provided to assess growth. Analysts have set a mean price target of CNY 23.05, implying a 124% upside from the current market price of CNY 10.28. This suggests strong expectations for future performance, though the company's current ROE and ROA are below industry norms. ### Risk Factors Liquidity risk is low, with ample cash reserves and a strong current ratio. Dilution risk is also low, with no immediate filing-based flags detected. However, the company's high price-to-earnings ratio of 133.16 and price-to-book ratio of 3.83 suggest potential overvaluation relative to earnings and book value. ### Recent Events No specific recent events are detailed in the provided data, but the company's financials and analyst estimates indicate a positive outlook. The absence of dilution or liquidity flags suggests stable operations and financial management.

30-day price · 2256-2.92 (-22.1%)
Low$10.28High$14.70Close$10.28As of18 May, 00:00 UTC
Profile
CompanyAbbisko Cayman Ltd
Ticker2256.HK
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Abbisko Cayman Ltd is a biotechnology company engaged in pharmaceuticals and medical research, generating revenue primarily through product sales and R&D activities.

Classification. Abbisko is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

### Capital Structure and Liquidity Abbisko maintains a strong liquidity position, with a current ratio of 4.98 and cash and equivalents of CNY 749.01 million, representing 31.8% of total assets. The company's debt-to-equity ratio is 0.16, indicating a conservative capital structure with minimal leverage. Custom valuations show a liquidity FPT of 1.2, suggesting robust short-term financial flexibility. ### Profitability and Returns The company's profitability is modest, with a net income of CNY 55.31 million and a return on equity (ROE) of 2.88%. These figures are below the industry median for ROE in the Biotechnology & Medical Research sector, which typically exceeds 10%. Gross profit equals total revenue, suggesting no cost of goods sold, which is unusual for a pharmaceutical company and may indicate a different business model or reporting structure. ### Segments and Geographic Exposure Abbisko's revenue is not segmented by geography or product in the provided data, but the company's operations are likely concentrated in China given the CNY financial reporting. There is no indication of significant international diversification. ### Growth Trajectory The company's revenue of CNY 612.12 million is stable, but there is no historical data provided to assess growth. Analysts have set a mean price target of CNY 23.05, implying a 124% upside from the current market price of CNY 10.28. This suggests strong expectations for future performance, though the company's current ROE and ROA are below industry norms. ### Risk Factors Liquidity risk is low, with ample cash reserves and a strong current ratio. Dilution risk is also low, with no immediate filing-based flags detected. However, the company's high price-to-earnings ratio of 133.16 and price-to-book ratio of 3.83 suggest potential overvaluation relative to earnings and book value. ### Recent Events No specific recent events are detailed in the provided data, but the company's financials and analyst estimates indicate a positive outlook. The absence of dilution or liquidity flags suggests stable operations and financial management.
Key takeaways
  • Abbisko has a strong liquidity position with a current ratio of 4.98 and significant cash reserves.
  • The company's profitability metrics, particularly ROE and ROA, are below industry medians.
  • Analysts have set a high mean price target of CNY 23.05, indicating strong growth expectations.
  • The company's capital structure is conservative, with a low debt-to-equity ratio of 0.16.
  • There are no immediate liquidity or dilution risks, but the high valuation multiples suggest potential overvaluation.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$612.1M
Gross profit$612.1M
Operating income$119.9M
Net income$55.3M
R&D
SG&A
D&A
SBC
Operating cash flow$79.3M
CapEx-$5.5M
Free cash flow$72.1M
Total assets$2.35B
Total liabilities$430.2M
Total equity$1.92B
Cash & equivalents$749.0M
Long-term debt$303.5M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$612.1M$119.9M$55.3M$72.1M
FY-1$504.0M$79.6M$28.3M$44.5M
FY-2$19.1M-$429.4M-$431.6M-$425.4M
FY-3$0.00-$492.9M-$495.6M-$502.6M
FY-4$22.7M-$1.81B-$1.81B-$1.81B
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$2.35B$1.92B$749.0M
FY-1$2.11B$1.96B$289.5M
FY-2$2.12B$1.98B
FY-3$2.49B$2.35B
FY-4$2.65B$2.54B
PeriodOCFCapExFCFSBC
FY0$79.3M-$5.5M$72.1M
FY-1-$12.9M-$7.4M$44.5M
FY-2-$444.7M-$12.3M-$425.4M
FY-3-$343.9M-$22.7M-$502.6M
FY-4-$169.7M-$12.3M-$1.81B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$10.28
Market cap$7.37B
Enterprise value$6.92B
P/E133.2
Reported non-GAAP P/E
EV/Revenue11.3
EV/Op income57.7
EV/OCF87.3
P/B3.8
P/Tangible book3.8
Tangible book$1.92B
Net cash$445.5M
Current ratio5.0
Debt/Equity0.2
ROA2.4%
ROE2.9%
Cash conversion1.4%
CapEx/Revenue-0.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric2256Activity
Op margin19.6%-2.9% medp25 -218.9% · p75 9.6%top quartile
Net margin9.0%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin100.0%47.8% medp25 27.6% · p75 68.9%top quartile
CapEx / revenue-0.9%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity16.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Observations
IR observations
Mean price target23.05 CNY
Median price target22.45 CNY
High price target32.50 CNY
Low price target17.90 CNY
Mean recommendation1.62 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count5.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.47 CNY
Last actual EPS0.09 CNY
Source: analysis-pipeline (hybrid)Generated: 2026-05-19 00:27 UTCJob: ec9244b0